Literature DB >> 19238112

An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome.

Taisuke Eguchi1, Yuichi Nomura, Teruto Hashiguchi, Kiminori Masuda, Michiko Arata, Daisuke Hazeki, Kentaro Ueno, Junichiro Nishi, Yoshifumi Kawano, Ikuro Maruyama.   

Abstract

We examined the serum values of high mobility group box 1 (HMGB1) in 36 patients with Kawasaki syndrome (KS) (29 responders and 7 poor-responders to initial intravenous immunoglobulin treatment). A mean value of HMGB1 of poor-responders was significantly elevated compared with those of responders (P = 0.0042). Among the 6 factors showing significant differences between responders and poor-responders including HMGB1 (admission illness day, white blood cell counts, C-reactive protein, aspartate aminotransferase, lactate dehydrogenase), values of HMGB1 showed the widest area under the receiver operating characteristic curve. In conclusion, an elevated HMGB1 value could be a potential marker for poor-responders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19238112     DOI: 10.1097/INF.0b013e31818ffe60

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

Review 1.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 3.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

Review 4.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

5.  The prognostic role of abnormal liver function in IVIG unresponsiveness in Kawasaki disease: a meta-analysis.

Authors:  Ling Liu; Wei Yin; Ruigeng Wang; Dongming Sun; Xuelian He; Yan Ding
Journal:  Inflamm Res       Date:  2015-12-08       Impact factor: 4.575

Review 6.  Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases.

Authors:  Norma Maugeri; Patrizia Rovere-Querini; Angelo A Manfredi
Journal:  Front Immunol       Date:  2016-05-19       Impact factor: 7.561

7.  Identifying genetic hypomethylation and upregulation of Toll-like receptors in Kawasaki disease.

Authors:  Ying-Hsien Huang; Sung-Chou Li; Lien-Hung Huang; Pao-Chun Chen; Yi-Yu Lin; Chiung-Chun Lin; Ho-Chang Kuo
Journal:  Oncotarget       Date:  2017-02-14

Review 8.  Association of serum/plasma high mobility group box 1 with autoimmune diseases: A systematic review and meta-analysis.

Authors:  Bin Zhu; Qing Zhu; Nanfang Li; Ting Wu; Shasha Liu; Shanshan Liu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

9.  Prednisolone Suppresses the Extracellular Release of HMGB-1 and Associated Inflammatory Pathways in Kawasaki Disease.

Authors:  Kentaro Ueno; Yuichi Nomura; Yasuko Morita; Yoshifumi Kawano
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

10.  Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.

Authors:  Takashi Inoue; Shokei Murakami; Kenji Matsumoto; Akio Matsuda
Journal:  Pediatr Rheumatol Online J       Date:  2020-10-06       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.